Subcutaneous immunotherapy in patients with eosinophilic esophagitis

Benjamin S. Robey; Swathi Eluri; Craig C. Reed; Maya R. Jerath; Michelle L. Hernandez; Scott P. Commins; Evan S. Dellon

doi:10.1016/j.anai.2019.02.022

Subcutaneous immunotherapy in patients with eosinophilic esophagitis

Benjamin S. Robey, Swathi Eluri, Craig C. Reed, Maya R. Jerath, Michelle L. Hernandez, Scott P. Commins, Evan S. Dellon

Division of Allergy & Immunology

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Original language	English
Pages (from-to)	532-533.e3
Journal	Annals of Allergy, Asthma and Immunology
Volume	122
Issue number	5
DOIs	https://doi.org/10.1016/j.anai.2019.02.022
State	Published - May 2019

Access to Document

10.1016/j.anai.2019.02.022

Cite this

@article{052d7dc50e824754997631cf05ddf1b6,

title = "Subcutaneous immunotherapy in patients with eosinophilic esophagitis",

author = "Robey, {Benjamin S.} and Swathi Eluri and Reed, {Craig C.} and Jerath, {Maya R.} and Hernandez, {Michelle L.} and Commins, {Scott P.} and Dellon, {Evan S.}",

note = "Funding Information: Funding Sources: This study was funded in part by NIH award T32 DK007634 (SE; CCR). It also used services from the NC Translational and Clinical Sciences (NC TraCS) Institute, which is supported by the National Center for Advancing Translational Sciences (NCATS) through Grant Award Number UL1TR002489. Funding Information: Disclosures: Dr. Dellon is a consultant for Adare, Alivio, Allakos, Banner, Calypso, Enumeral, EsoCap, GSK, Gossamer Bio, Receptos/Celegene, Regeneron, Robarts, and Shire, receives research funding from Allakos , Adare , GSK , Meritage , Miraca , Nutricia , Receptos/Celgene , Regeneron , and Shire , and has received an educational grant from Allakos , Banner , and Holoclara . None of the other authors report and potential conflicts of interest with this study. Funding Information: Disclosures: Dr. Dellon is a consultant for Adare, Alivio, Allakos, Banner, Calypso, Enumeral, EsoCap, GSK, Gossamer Bio, Receptos/Celegene, Regeneron, Robarts, and Shire, receives research funding from Allakos, Adare, GSK, Meritage, Miraca, Nutricia, Receptos/Celgene, Regeneron, and Shire, and has received an educational grant from Allakos, Banner, and Holoclara. None of the other authors report and potential conflicts of interest with this study.Funding Sources: This study was funded in part by NIH award T32 DK007634 (SE; CCR). It also used services from the NC Translational and Clinical Sciences (NC TraCS) Institute, which is supported by the National Center for Advancing Translational Sciences (NCATS) through Grant Award Number UL1TR002489.",

year = "2019",

month = may,

doi = "10.1016/j.anai.2019.02.022",

language = "English",

volume = "122",

pages = "532--533.e3",

journal = "Annals of Allergy, Asthma and Immunology",

issn = "1081-1206",

number = "5",

}

TY - JOUR

T1 - Subcutaneous immunotherapy in patients with eosinophilic esophagitis

AU - Robey, Benjamin S.

AU - Eluri, Swathi

AU - Reed, Craig C.

AU - Jerath, Maya R.

AU - Hernandez, Michelle L.

AU - Commins, Scott P.

AU - Dellon, Evan S.

N1 - Funding Information: Funding Sources: This study was funded in part by NIH award T32 DK007634 (SE; CCR). It also used services from the NC Translational and Clinical Sciences (NC TraCS) Institute, which is supported by the National Center for Advancing Translational Sciences (NCATS) through Grant Award Number UL1TR002489. Funding Information: Disclosures: Dr. Dellon is a consultant for Adare, Alivio, Allakos, Banner, Calypso, Enumeral, EsoCap, GSK, Gossamer Bio, Receptos/Celegene, Regeneron, Robarts, and Shire, receives research funding from Allakos , Adare , GSK , Meritage , Miraca , Nutricia , Receptos/Celgene , Regeneron , and Shire , and has received an educational grant from Allakos , Banner , and Holoclara . None of the other authors report and potential conflicts of interest with this study. Funding Information: Disclosures: Dr. Dellon is a consultant for Adare, Alivio, Allakos, Banner, Calypso, Enumeral, EsoCap, GSK, Gossamer Bio, Receptos/Celegene, Regeneron, Robarts, and Shire, receives research funding from Allakos, Adare, GSK, Meritage, Miraca, Nutricia, Receptos/Celgene, Regeneron, and Shire, and has received an educational grant from Allakos, Banner, and Holoclara. None of the other authors report and potential conflicts of interest with this study.Funding Sources: This study was funded in part by NIH award T32 DK007634 (SE; CCR). It also used services from the NC Translational and Clinical Sciences (NC TraCS) Institute, which is supported by the National Center for Advancing Translational Sciences (NCATS) through Grant Award Number UL1TR002489.

PY - 2019/5

Y1 - 2019/5

UR - http://www.scopus.com/inward/record.url?scp=85063329266&partnerID=8YFLogxK

U2 - 10.1016/j.anai.2019.02.022

DO - 10.1016/j.anai.2019.02.022

M3 - Article

C2 - 30831258

AN - SCOPUS:85063329266

SN - 1081-1206

VL - 122

SP - 532-533.e3

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

IS - 5

ER -

Subcutaneous immunotherapy in patients with eosinophilic esophagitis

Access to Document

Other files and links

Cite this